Aquatic Capital Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Aquatic Capital Management’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-27,712	Closed	-$1.42M	–	1318
2024 Q4	$1.42M	Buy	+27,712	New	+$1.55M	0.04%	455
2024 Q2	–	Sell	-7,100	Closed	-$332K	–	1296
2024 Q1	$332K	Buy	+7,100	New	+$278K	0.01%	645
2023 Q3	–	Sell	-3,900	Closed	-$70K	–	1311
2023 Q2	$70K	Buy	+3,900	New	+$77.8K	﹤0.01%	928
2022 Q2	–	Sell	-200	Closed	-$4K	–	1260
2022 Q1	$4K	Sell	200 -3,300	-94%	-$66.8K	0.01%	857
2021 Q4	$99K	Buy	+3,500	New	+$86.3K	0.19%	132

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Aquatic Capital Management's CRNX Position: Q1 2025 in Review

Aquatic Capital Management sold out of Crinetics Pharmaceuticals (CRNX) in Q1 2025, closing a stake of 27,712 shares — an estimated $1.42M sold.

Aquatic Capital Management first reported a position in CRNX in Q4 2021 and held it in 5 quarters. The position peaked at $1.42M in Q4 2024. 227 funds tracked by Wall St. Rank hold CRNX as of Q1 2025.

Aquatic Capital Management reported no remaining Crinetics Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Aquatic Capital Management sold 27,712 Crinetics Pharmaceuticals shares in Q1 2025, an estimated $1.42M.
Aquatic Capital Management first reported a position in Crinetics Pharmaceuticals in Q4 2021 and held it in 5 quarters.
Aquatic Capital Management's Crinetics Pharmaceuticals position peaked at $1.42M in Q4 2024.
227 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2025.

Based on Aquatic Capital Management's 13F filing for Q1 2025, filed 15 May 2025.